half-life comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
Storage conditions for semaglutide depend heavily on the presentation. Lyophilized research powder is generally kept at two to eight degrees Celsius in a sealed container, protected from light and moisture. Manufacturer labeling for finished injectable products specifies refrigeration before first use, with defined in-use periods at room temperature afterward. The oral tablet form is stored at controlled room temperature and is more tolerant of short excursions. Temperature excursions should be documented rather than inferred.
Peptide degradation follows several routes. Hydrolysis cleaves the backbone at susceptible residues, oxidation targets methionine and tryptophan side chains, and aggregation produces higher-molecular-weight species that are difficult to reverse. Light exposure accelerates oxidation, which is why amber glass or opaque secondary packaging is common. Repeated freeze-thaw cycles promote aggregation and are best avoided. Stability-indicating methods detect these changes before they become visible.
Quality control for research material typically involves reversed-phase HPLC for purity and identity, mass spectrometry for molecular weight confirmation, and Karl Fischer titration for residual water content. Peptide content is often reported as the mass of actual peptide rather than total powder mass, since counterions and water contribute to the latter. A certificate of analysis should list the method used for each specification. Limits and acceptance criteria vary by supplier and by intended application.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Acylated GLP-1 receptor agonist | 31-residue synthetic peptide |
| Molecular formula | C187H291N45O59 | established for the free peptide |
| Appearance | White to off-white powder | as supplied before formulation |
| Solubility | Freely soluble in water | aqueous buffers near neutral pH |
| Typical storage | 2 to 8 degrees Celsius, protected from light | powder and solution forms differ in shelf life |
Identity and purity are usually assessed by reverse-phase high-performance liquid chromatography coupled to mass spectrometry. Retention time and observed mass are compared against a reference standard run under identical conditions. Impurity profiles reveal deamidation products, oxidized methionine variants, and truncated fragments that arise during synthesis or storage. Peptide mapping through enzymatic digestion confirms the primary sequence, while amino acid analysis offers an independent check on overall composition.
Stability studies examine how temperature, pH, and moisture influence degradation rates over time. In aqueous solution, hydrolysis and deamidation accelerate as pH moves away from mildly acidic conditions. Light exposure and residual metal ions can also trigger oxidation of susceptible residues. Accelerated aging at elevated temperature is used to estimate shelf life, though extrapolation to room temperature carries uncertainty because individual degradation pathways do not always scale predictably.
Lyophilized semaglutide powder is typically held at minus twenty degrees Celsius for long-term storage. At that temperature, solid-state degradation reactions proceed slowly and the peptide remains intact for extended periods. Repeated freeze-thaw cycles are best avoided because they promote aggregation and can shift the proportion of monomeric peptide present. Working aliquots are often prepared so that each portion is thawed only once, and desiccant is placed inside the vial to limit moisture uptake.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Municipal website Singer, Isidore; et al., eds. (1901–1906). "Jabneh". The Jewish Encyclopedia. New York: Funk & Wagnalls. Yavneh Yields Over a Hundred Philistine Cult Stands Archived 2012-05-31 at the Wayback Machine Biblical Archaeology Review "Jamnia" . Encyclopædia Britannica (11th ed.). 1911. 2008 salvage excavation report, Orit Segal at Excavations and Surveys in Israel, 5 July 2011. Accessed 22 Feb 2017.
==== 1.G Viral fusion pores ==== 1.G.1 The Viral Pore-forming Membrane Fusion Protein-1 (VMFP1) Family 1.G.2 The Viral Pore-forming Membrane Fusion Protein-2 (VMFP2) Family 1.G.3 The Viral Pore-forming Membrane Fusion Protein-3 (VMFP3) Family 1.G.4 The Viral Pore-forming Membrane Fusion Protein-4 (VMFP4) Family 1.G.5 The Viral Pore-forming Membrane Fusion Protein-5 (VMFP5) Family 1.G.6 The Hepadnaviral S Fusion Protein (HBV-S Protein) Family 1.G.7 The Reovirus FAST Fusion Protein (R-FAST) Family 1.G.8 The Arenavirus Fusion Protein (AV-FP) Family 1.G.9 The Syncytin (Syncytin) Family 1.G.10 The Herpes Simplex Virus Membrane Fusion Complex (HSV-MFC) Family 1.G.11 Poxvirus Cell Entry Protein Complex (PEP-C) Family 1.G.12 The Avian Leukosis Virus gp95 Fusion Protein (ALV-gp95) Family 1.G.13 The Orthoreovirus Fusion-associated Small Transmembrane (FAST) Family 1.G.14 The Influenza Virus Hemagglutinin/Fusion Pore-forming Protein (Influenza-H/FPP) Family 1.G.15 The Autographa californica Nuclear Polyhedrosis Virus Major Envelope Glycoprotein GP64 (GP64) Family 1.G.16 The Human Immunodeficiency Virus Type 1 (HIV-1) Fusion Peptide (HIV-FP) Family 1.G.17 The Bovine Leukemia Virus Envelop Glycoprotein (BLV-Env) Family 1.G.18 The SARS-CoV Fusion Peptide in the Spike Glycoprotein Precursor (SARS-FP) Family 1.G.19 The Rotavirus Pore-forming Membrane Fusion Complex (Rotavirus MFC) Family 1.G.20 The Hantavirus Gc Envelope Fusion Glycoprotein (Gc-EFG) Family 1.G.21 The Epstein Barr Virus (Human Herpes Virus 4) Gp42 (Gp42) Family 1.G.22 The Cytomegalovirus (Human Herpesvirus 5) Glycoprotein gO (gO) Family
In immunology, an antigen (Ag) is a molecule, or portion thereof, that can bind to a specific antibody or T-cell receptor. The presence of antigens in the body may trigger an immune response. Antigens can be proteins, peptides (amino acid chains), polysaccharides (chains of simple sugars), lipids, or nucleic acids. Antigens exist on normal cells, cancer cells, parasites, viruses, fungi, and bacteria. Antigens are recognized by antigen receptors, including antibodies and T-cell receptors. Diverse antigen receptors are made by cells of the immune system so that each cell has a specificity for a single antigen. Upon exposure to an antigen, only the lymphocytes that recognize that antigen are activated and expanded, a process known as clonal selection. In most cases, antibodies are antigen-specific, meaning that an antibody can only react to and bind one specific antigen; in some instances, however, antibodies may cross-react to bind more than one antigen. The reaction between an antigen and an antibody is called the antigen-antibody reaction. Antigen can originate either from within the body ("self-protein" or "self antigens") or from the external environment ("non-self"). The immune system identifies and attacks "non-self" external antigens. Antibodies usually do not react with self-antigens due to negative selection of T cells in the thymus and B cells in the bone marrow. The diseases in which antibodies react with self antigens and damage the body's own cells are called autoimmune diseases.
Sources: en.wikipedia.org
During 1942, the brigade focused on the "Rail War", conducting extensive sabotage operations on the Vitebsk-Nevel and Polotsk-Nevel railway lines. They also routed German garrisons at the Bychikha and Yezerishche stations and in various villages in the Gorodok District. In early 1943, German Command launched a series of anti-partisan sweeps. Following a Period of intense combat near the villages of Tsari and Budnista, the brigade, which had numbered 597 partisans, was forced to retreat across the frontlines into Soviet-held territory on March 4th, 1943, leading to the brigade's temporary dissolution.
==== Alzheimer's disease ==== Decreased expression of ChAT is one of the hallmarks of Alzheimer's disease. Patients with Alzheimer's disease show a 30 to 90% reduction in activity in several regions of the brain, including the temporal lobe, the parietal lobe and the frontal lobe. However, ChAT deficiency is not believed to be the main cause of this disease.
The 23S rRNA is a 2,904 nucleotide long (in E. coli) component of the large subunit (50S) of the bacterial/archean ribosome and makes up the peptidyl transferase center (PTC). The 23S rRNA is divided into six secondary structural domains titled I-VI, with the corresponding 5S rRNA being considered domain VII. The ribosomal peptidyl transferase activity resides in domain V of this rRNA, which is also the most common binding site for antibiotics that inhibit translation, making it a target for ribosomal engineering. A well-known member of this antibiotic class, chloramphenicol, acts by inhibiting peptide bond formation, with recent 3D-structural studies showing two different binding sites depending on the species of ribosome. Numerous mutations in domains of the 23S rRNA with Peptidyl transferase activity have resulted in antibiotic resistance. 23S rRNA genes typically have higher sequence variations, including insertions and/or deletions, compared to other rRNAs. The eukaryotic homolog of the 23S LSU rRNA is the 28S ribosomal RNA, with a region filled by the 5.8S ribosomal RNA.
== Pathogenesis == The cells of adipose (fat) tissue synthesize hormones known as adipokines. In humans, dysfunction of adipose tissue, even in cases without obesity, has been associated with the development of insulin resistance, hypertension, systemic inflammation, and increased risk of blood clots (thrombosis). The inflammation produced by these hormones are thought to inflame adipose tissue, leading to the production of more adipokines and perpetuation of the cycle, and a constant low-level, pro-inflammatory state. Although it is suspected that a similar mechanism occurs in horses, further research is needed.
Sources: en.wikipedia.org
=== Diagnostic tests === The initial tests for thalassemias are: Complete blood count (CBC): Checks the number, size, and maturity of blood cells. Hemoglobin of less than 10 g/dl may indicate a carrier, below 7 g/dl is indicative of thalassemia major. In thalassemia major, mean corpuscular volume (MCV) are less than 70 fl, in thalassemia intermedia, MCV levels are below 80 fl (The normal range for MCV is 80–100 fl). The Mentzer index can be a pointer for diagnosis of thalassemia; it can be calculated from a CBC report. Peripheral blood smear: A blood smear examined under a microscope can show red blood cells that are abnormal in shape (poikilocytosis or codocytes), color (hypochromic), or size (microcytic), as well as those with abnormal inclusions (Heinz bodies). Serum iron and ferritin: these tests are needed to rule out iron-deficiency anemia. For an exact diagnosis, the following tests can be performed:
For instance, the Lois lab at Caltech is using engineered artificial ligands and receptors on neurons to trace information flow in the brain. They are specifically using ligand-induced intramembrane proteolysis to unravel the wiring of the brain in Drosophila and other models. When the artificial ligand on one neuron binds to the receptor on another, GFP expression is activated in the acceptor neuron demonstrating the usefulness of ligand binding assays in neuroscience and biology.
Lenway, Stefanie Ann (1988). "Between war and Commerce: economic sanctions as a tool of statecraft". International Organization. 42 (2). Cambridge University Press: 397–426. doi:10.1017/S0020818300032860. S2CID 154337246. Ong, Andrew (2023). Stalemate: Autonomy and Insurgency on the China-Myanmar Border. Cornell University Press. ISBN 978-1-5017-7071-5. JSTOR 10.7591/j.ctv2t8b78b. Zhang, Chuchu (2025). China's Changing Role in the Middle East: Filling a Power Vacuum?. Changing Dynamics in Asia-Middle East Relations series. Abingdon, Oxon; New York, NY: Routledge. ISBN 978-1-032-76275-3.
==== UPMC Passavant ==== UPMC Passavant is UPMC's tertiary care hospital of Pittsburgh's northern suburbs that consist of two campuses, one in McCandless and another in Cranberry Township with a combined 423 beds. Founded by Lutherans in 1849, Passavant was the first Protestant hospital built in the United States. In 1964, Passavant moved from the City of Pittsburgh to its location in McCandless to serve the communities of northern Allegheny and southern Butler counties. Passavant merged with UPMC in 1997 and in 2002, as part of UPMC's acquisition of St. Francis Medical Center for the conversion of its flagship facility into the new Children's Hospital of Pittsburgh, UPMC converted St. Francis' hospital in Cranberry into a satellite campus of UPMC Passavant. In 2010, a seven-story 188,000 square foot patient pavilion was opened on the McCandless campus bringing total beds there to 399.
=== Aryl halide-stapled peptides === Sufficiently electrophilic aryl halides have been used as staples as they can bridge two amino acids with nucleophilic side chains, most notably two cysteines. These include fluorobenzenes and dichlorotetrazine. The diversity of aryl halides in terms of electrophilicity and regiochemistry offers a way of tuning the reactivity and tightness of the staple. The latter aspect has been applied to the tuning of secondary structure of small peptides.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and neutral endopeptidases. Semaglutide carries a non-natural amino acid at position eight that blocks that cleavage, and a fatty diacid side chain that binds albumin. The result is a much longer duration of action than the native hormone.
The fatty diacid chain associates strongly with serum albumin, which keeps the peptide in circulation and shields it from rapid renal clearance. Bound peptide is released gradually, producing a sustained receptor signal. This mechanism also reduces the peak-to-trough variation seen with shorter-acting analogues.
The balance between peripheral receptor activation and signalling in the central nervous system is not fully resolved. The extent to which slowed gastric emptying accounts for reduced energy intake, compared with direct effects on appetite circuits, is debated. Long-term effects on lean mass and on tissues outside the gut and brain are still under study.
Sealed, protected from light, and refrigerated at two to eight degrees Celsius for most research material. Desiccated storage limits moisture uptake. Allow the vial to reach room temperature before opening to prevent condensation.